SSR146977盐酸盐 | 264618-44-2

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 中文名称: SSR146977盐酸盐
• 中文别名: N'-[1-[3-[(3R)-1-苯甲酰基-3-(3,4-二氯苯基)-3-哌啶基]丙基]-4-苯基-4-哌啶基]-N,N-二甲基脲
• 英文名称: 3-[1-[3-[(3R)-1-(benzoyl)-3-(3,4-dichlorophenyl)piperidin-3-yl]propyl]-4-phenylpiperidin-4-yl]-1,1-dimethylurea
• 英文别名: 3-[1-[3-[(3R)-1-benzoyl-3-(3,4-dichlorophenyl)piperidin-3-yl]propyl]-4-phenylpiperidin-4-yl]-1,1-dimethylurea
• CAS: 264618-44-2
• 化学式: C₃₅H₄₂Cl₂N₄O₂
• 分子量: 621.6
• InChiKey: XWPBINGFFFZAOZ-UMSFTDKQSA-N

物化性质

• 密度：
  1.26
• 溶解度：
  <65.81mg/ml，溶于 DMSO； <65.81mg/ml，在乙醇中

计算性质

• 辛醇/水分配系数(LogP)：
  6.8
• 重原子数：
  43
• 可旋转键数：
  8
• 环数：
  5.0
• sp3杂化的碳原子比例：
  0.43
• 拓扑面积：
  55.9
• 氢给体数：
  1
• 氢受体数：
  3

反应信息

• 作为产物：
  描述：

  、 4-(N',N'-dimethylureido)-4-phenylpiperidine p-toluenesulphonate 在 作用下， 生成 SSR146977盐酸盐
  参考文献：
  名称：

  Ureidopiperidine derivatives as selective human NK3 receptor antagonists

  摘要：

  本发明涉及式（I）的化合物，其可以是外消旋或光学纯形式，以及制备它们的方法和含有它们的药物组合物。所述化合物是选择性NK3受体拮抗剂。

  公开号：

  US06465489B1

文献信息

• PROPHYLACTIC OR THERAPEUTIC AGENT AND MEDICINAL COMPOSITION FOR IL-31-MEDIATED DISEASE
  申请人：Kyushu University, National University Corporation

  公开号：EP3881843A1

  公开（公告）日：2021-09-22

  A prophylactic or therapeutic agent for an IL-31 mediated disease, said agent comprising a neurokinin B signal blocker.

  一种 IL-31 介导疾病的预防或治疗药物，所述药物包括神经激肽 B 信号阻断剂。
• NK-3 receptor antagonists for therapeutic or cosmetic treatment of excess body fat
  申请人：OGEDA SA

  公开号：US10624890B2

  公开（公告）日：2020-04-21

  Disclosed is use of NK3R antagonists for the therapeutic treatment of pathological excess body fat and/or prevention of body fat gain in patients. Also disclosed is a cosmetic method for stimulating the loss of excess of body fat, including the administration of a NK-3 receptor antagonist.

  本发明公开了 NK3R 拮抗剂在治疗病理性体脂过多和/或预防患者体脂增加方面的用途。还公开了一种刺激减少体内多余脂肪的美容方法，包括施用 NK-3 受体拮抗剂。
• Methods and compositions for treating vasomotor symptoms
  申请人：UNIVERSITY OF WASHINGTON THROUGH ITS CENTER FOR COMMERCIALIZATION

  公开号：US11083726B2

  公开（公告）日：2021-08-10

  The present disclosure is generally directed to compositions and methods for treating or limiting development of vasomotor symptoms in a subject.

  本公开总体上涉及用于治疗或限制受试者血管运动症状发展的组合物和方法。
• Method For Treating Or Preventing Hot Flushes
  申请人：IMPERIAL INNOVATIONS LIMITED

  公开号：US20160220555A1

  公开（公告）日：2016-08-04

  The invention provides a neurokinin 3 receptor (NKR3) antagonist for use in the treatment, prevention or amelioration of hot flushes in a human subject, for example a menopausal woman or a patient undergoing cancer therapy which affects secretion of sex steroids. The invention also provides a NKR3 antagonist together with a further active agent, and a composition and a kit comprising a NKR3 antagonist and a further active agent. The invention further provides a NKR3 agonist or exogenous NKB for the induction of hot flushes in a human subject.
• Methods and Compositions for Treating Vasomotor Symptoms
  申请人：UNIVERSITY OF WASHINGTON THROUGH ITS CENTER FOR COMMERCIALIZATION

  公开号：US20170020855A1

  公开（公告）日：2017-01-26

  The present disclosure is generally directed to compositions and methods for treating or limiting development of vasomotor symptoms in a subject.